{"id":96,"date":"2019-05-13T10:27:56","date_gmt":"2019-05-13T10:27:56","guid":{"rendered":"https:\/\/www.ojaseyehospital.com\/blog\/?p=96"},"modified":"2019-05-13T10:27:58","modified_gmt":"2019-05-13T10:27:58","slug":"glaucoma","status":"publish","type":"post","link":"https:\/\/www.ojaseyehospital.com\/blog\/glaucoma\/","title":{"rendered":"Glaucoma"},"content":{"rendered":"\n

A new innovation in Glaucoma treatment<\/strong><\/a>. The Beacon Aqueous Microshunt (MicroOptix) – \u00a0the brain child of David Brown, MD, 20 years in development-is 3.1 mm in length with an external flange width of 7 mm. It is implanted into a paracentesis-like incision, allowing aqueous to flow through a central channel.<\/p>\n

\u00a0Mitigation against retrograde flow of pathogens would be a concern for such an idea. However, Dr. Riedel said that this is prevented 1 ) by shear stress and 2) by the polyethylene glycol material that composes the central layer of the three-layer device. Polyethylene glycol is considered the gold standard of anti-bio fouling materials. It is super hydrophilic, and it prevents adherence of protein and bacteria to the channel wall, Dr. Riedel explained.<\/p>\n

In a porcine animal model followed to 6 months, Dr. Riedel noted no infections and significant, persistent IOP lowering. An aggressive bacterial challenge with the device on eight animals did not result in eye infection, Dr. Riedel said.<\/p>\n

Preliminary data from an early bird study in the U.S. and E.U. has shown a mean IOP ( eye pressure ) of 13 mm Hg at 6 months, compared to a baseline mean of 27 mm Hg that was medicated with no washout of patients. Eighty-seven percent of patients showed a 20% reduction in pressure compared to baseline and all patients except one were off all medications postop. Most patients, Dr. Riedel said, were vet or extremely comfortable at 6 months.<\/p>\n

In terms of safety, there were no infections or uveitis, no dislocations or device migration, and no sight-threatening complications. There were there device blockages, two of which resolved completely with no or minimal in tervention. The third was remove for persistent blockage.<\/p>\n

Dr. Riedel said investigators will soon conduct a prospective, multicenter study to evaluate safety and efficacy in refractory glaucoma.<\/p>\n\n","protected":false},"excerpt":{"rendered":"

A new innovation in Glaucoma treatment. The Beacon Aqueous Microshunt (MicroOptix) – \u00a0the brain child of David Brown, MD, 20 years in development-is 3.1 mm in length with an external flange width of 7 mm. It is implanted into a paracentesis-like incision, allowing aqueous to flow through a central channel. \u00a0Mitigation against retrograde flow of<\/p>\n","protected":false},"author":1,"featured_media":41,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[34,62],"class_list":["post-96","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glaucoma","tag-best-eye-hospital-in-mumbai","tag-glaucoma-treatment-in-mumbai"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t